IDX 375

Drug Profile

IDX 375

Alternative Names: IDX375

Latest Information Update: 04 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idenix Pharmaceuticals; University of Cagliari
  • Developer Idenix Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 31 Dec 2011 Discontinued - Phase-I for Hepatitis C in Europe (PO)
  • 31 Dec 2011 Discontinued - Phase-II for Hepatitis C in USA (PO)
  • 28 Feb 2011 Efficacy and safety data from a phase I trial in Hepatitis C released by Idenix Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top